Roche's Vabysmo Shows Sustained Two-Year Results In SALWEEN Study, With 61% Of PCV Patients Achieving Extended 20-Week Dosing

ROCHE HOLDINGS AG
ROCHE HOLDINGS AG

ROCHE HOLDINGS AG

RHHBY

0.00

ROCHE HOLDINGS AG

RHHBF

0.00
  • The SALWEEN study showed significant improvements in vision and retinal health
  • More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions
  • By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden
  • Vabysmo was well tolerated with a consistent long-term safety profile
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.